Atea Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Noncurrent
Atea Pharmaceuticals, Inc. (AVIR) had Debt Securities, Available-for-sale, Noncurrent of $0 as of 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent · last filed 2025-11-12
- 2025-09-30: Debt Securities, Available-for-sale, Noncurrent $0.00.
- 2025-06-30: Debt Securities, Available-for-sale, Noncurrent $0.00.
- 2025-03-31: Debt Securities, Available-for-sale, Noncurrent $0.00.
- 2024-12-31: Debt Securities, Available-for-sale, Noncurrent $0.00.
| Period end | Debt Securities, Available-for-sale, Noncurrent |
|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-12 |
| 2024-12-31 | $0.00 10-Q · filed 2025-11-12 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-06 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-08 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-28 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |